SCYL3

Across TCGA pan-cancer cohorts, SCYL3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SCYL3 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SCYL3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SCYL3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where SCYL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.504	0.306	<.001	59	view →
HNSC	DFS	Quartile	III,IV	0.961	0.660	.002	43	view →
LSCC	DFS	Quartile	All	0.650	0.937	.001	16	view →
CCRCC	DFS	Median	All	1.000	0.542	.005	14	view →
UCEC	OS	Median	All	0.968	0.860	.042	6	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.885	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SCYL3–PDAC (DFS)

Open the PDAC breakdown →